Tackling RAGE interaction

Many of the compounds in development for Alzheimer's disease are seeking to block the formation of amyloid beta. TransTech Pharma Inc. is taking a complementary approach focused on preventing the damage amyloid beta causes. Pfizer Inc. last week took exclusive worldwide rights to the company's receptor for advanced glycation endproducts (RAGE) technology in a deal that PFE said is complementary to its purchase of Rinat Neuroscience Corp. earlier this year.

TransTech's approach is based on preventing the interaction between RAGE and its ligand, amyloid beta...